Ferrer, Treeway Partner on Development and Commercialization of ALS Treatment

Ferrer and Treeway, have entered into a license agreement for the development and commercialization of an oral formulation of edaravone (TW001/FNP122).

International pharmaceutical company, Ferrer, and clinical-stage biotechnology company, Treeway, have entered into a license agreement for the development and commercialization of an oral formulation of edaravone (TW001/FNP122).

According to an Oct. 20, 2021 press release, the medicine will be used for the treatment of Amyotrophic Lateral Sclerosis (ALS) in certain territories, which will include Europe and some Asian countries. Ferrer will be responsible for advancing the development and commercialization of the drug and will make royalty payments to Treeway once certain milestones have been met.

“Guided by patients, we have developed TW001/FNP122 through the early stages of development,” said Inez de Greef, CEO at Treeway, in the press release. “We are therefore delighted that Ferrer has committed to advance our lead product to the required pivotal Phase III trial and make it available for ALS patients in large parts of the world.”

“Driven by our purpose of bringing transformative products to patients the world over, we are pleased to enter the agreement with Treeway and look forward to patients benefiting from improved treatment options,” added Oscar Pérez, Ferrer’s chief business development and licensing officer, in the press release. “TW001/FNP122 is the perfect fit for Ferrer’s strategy to bring new molecules to late-stage clinical development, registration and market entry in the field of neurological disorders and strengthen our pipeline for the coming years.”

Source: Ferrer